Teva Shares Rise Following FDA Approval of Migraine Drug
Teva’s new migraine drug is forecasted to bring in $500 million in sales annually
Shares of Israeli drugmaker Teva Pharmaceutical Industries Ltd. rose as much as 6% in after-hours trading on Friday, following the company’s announcement that it received the U.S. Food and Drug Administration’s approval for its new migraine injection, Ajovy.
For daily updates, subscribe to our newsletter by clicking here.
Teva’s shares now trade at $22.85 per share, a 17.2% rise since the beginning of 2018. This following a sharp decline in the company’s stock in recent years—a 46% decile in share value in 2017 and a 43% decline in 2016.
Teva CEO Kåre Schultz. Photo: Yuval Chen
Ajovy, known generically as fremanezumab, is a preventive treatment administered monthly or quarterly, with a U.S. wholesale price tag of $575 for a monthly dose and $1,725 for a quarterly dose. The price point places Ajovy in direct competition with another monthly migraine injection, Aimovig, sold in the U.S. by Amgen Inc. and Novartis AG since May.
Teva’s new migraine drug is forecasted to bring in $500 million in sales annually, according to Deutsche Bank.
After dropping sharply in the first half of the year, Teva’s sales in North America have suffered an additional blow in July when Mylan N.V. decided to cut the price tag on its generic version to Teva’s flagship drug Copaxone by 60%. Since its introduction in 1996, the Multiple Sclerosis drug has been Teva’s primary cash cow, netting the company more than $40 billion over the years. In 2016. The year Teva’s patent for Copaxone expired, the drug accounted for a fifth of its revenues.
The FDA approved Mylan's generic versions of the drug in October 2017. At the time, Teva was already spiraling downwards, with a plummeting stock price and growing concerns about its ability to carry a debt of around $35 billion, accrued as a result of its ill-advised 2016 acquisition of Allergan's generic unit Actavis.
In December 2017, shortly after naming Kåre Schultz as its new CEO, Teva announced a cost-cutting plan to deal with the company’s heavy debt load. By the second quarter of 2018, Teva managed to reduce its total base cost by $1.1 billion, mainly via significant layoffs. The company intends to reduce its total base cost by $3 billion by the end of 2019, also by asset divestment and portfolio streamlining, which will have an impact on the company's sales and bottom line. Those changes are expected to improve Teva's operating profit as of 2019, and especially as of 2020.
- Available Cash Prompts Teva to Make $400 Million Debt Tender Offer
- Teva Outsources Manufacturing in Anticipation of Israeli Plant Closure
- Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
In August, Teva announced its debt has decreased to around $30 billion.
On Friday, Bloomberg reported that Teva is looking to offload its Icelandic generic drug unit Medis, which it bought in 2016. Citing anonymous sources Bloomberg reported that the unit is garnering interest from companies such as Swedish pharmaceutical company Recipharm AB and Brazil’s EMS, as well as other bidders including private equity firms. Medis’ sale could bring in some $500 million, Bloomberg reported.
Teva has yet to comment on Bloomberg's report.
